Hematology & Oncology Doctors in Paoli, PA Accepting Medicare

7 Hematology & Oncology doctors found. Showing 1 - 7

Dr. Lisa R Kallenbach, M.D. Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2 Industrial Blvd, Ste 110, Paoli, PA 19301 Phone: 610-725-0650    Fax: 610-725-9583

Dr. Michael B Dabrow, DO Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 255 W Lancaster Ave, Cancer Center @ Paoli Hospital, Paoli, PA 19301 Phone: 484-565-1600    Fax: 610-647-2006

Dr. Christine E Szarka, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 255 W. Lancaster Ave., Paoli, PA 19301 Phone: 484-565-1600    Fax: 610-647-2006

Stephen Cary Fox, M.D., FACP Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 21 Industrial Blvd, Suite 204, Paoli, PA 19301 Phone: 610-647-2747    Fax: 610-640-3870

Dr. Michel C Hoessly, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2 Industrial Blvd, Ste 110, Paoli, PA 19301 Phone: 610-725-0650    Fax: 610-725-9583

Jennifer L Armstrong, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2 Industrial Blvd, Ste 110, Paoli, PA 19301 Phone: 610-725-0650    Fax: 610-725-9583

Sandra Lynn Urtishak, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 255 W. Lancaster Ave., Paoli, PA 19301 Phone: 484-565-1600    Fax: 610-647-2006

News Archive

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.

Autoimmune initiates steps to enhance shareholder value, retains Junewicz & Co. as its financial advisor

AutoImmune Inc. today announced that its Board of Directors has authorized the exploration of a full range of strategic alternatives available to the Company in order to enhance shareholder value. AutoImmune has retained Junewicz & Co. as its financial advisor for this evaluation process.

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

Read more Medical News

› Verified 2 days ago